Health Dictionary Find a Doctor

Cavernous sinus thrombosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: CST, thrombosis of the cavernous intracranial sinus, cavernous sinus syndrome, parasellar lesions, carotid-cavernous fistulas, C-C fistulas,

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

Historical Perspective

Cerebral sinus thrombosis was first discovered by Ribes a french physician, in 1825. Ribes discovered the cavernous sinus thrombosis during an autopsy of a 45-year-old patient with headaches, epileptic seizures and delirium. The first postpartum cerebral sinus thrombosis first discovered by John Abercrombie, a Scottish physician, in a 24-year-old woman who developed headache and seizures 2 weeks after an unremarkable delivery In 1828. A subsequent autopsy revealed thrombosis of the superior sagittal sinus and cortical veins.

Classification

The Jefferson classification and Ishikawa classification have been used to localize cavernous sinus lesions. Based upon the location of the intracranial orifice of the optic canal and the entry of the maxillary nerve into the cavernous sinus, lesions may be classified in the Ishikawa and the Jefferson classification scheme into three groups: Anterior lesions, middle lesions and posterior lesions. Although more patients could be classified using the Ishikawa classification, there is no advantage of Ishikawa classification over Jefferson with regard to determination of etiology of cavernous sinus lesions.

Pathophysiology

The cavernous sinus which is a true dural venous sinus, is irregularly shaped, trabeculated cavity in the base of the skull. The cavernous sinus receives blood via the superior and inferior ophthalmic veins through the Superior orbital fissure and superficial cortical veins. The Cavernous sinus is connected to the basilar plexus of veins posteriorly. There are some important nerves and arteries pass through the cavernous sinus, include: The internal carotid artery (carotid siphon), cranial nerve III, cranial nerve IV, cranial nerve V branches and cranial nerve VII. Infection from the face may reach the cavernous sinus through its many anastomotic connections, with severe consequences. The cavernous sinus drains by two larger channels, the superior and inferior petrosal sinuses, ultimately into the internal jugular vein via the sigmoid sinus, also draining with emissary vein to pterygoid plexus. These sinuses are just lateral and superior to the sphenoid sinus and are immediately posterior to the optic chiasm. Each cavernous sinus is formed between layers of the dura mater, and multiple connections exist between the 2 sinuses. It is understood that the main cause of cavernous sinus thrombosis is bacterial infections. Staphylococcus aureus may account for two-thirds of cases of cavernous sinus thrombosis. Other typical organisms include: streptococcus species (approximately 20% of cases), pneumococcus (5%),gram-negative species such as Proteus, hemophilus, pseudomonas, fusobacterium, bacteroides and gram-positive species such as Corynebacterium and Actinomyces. In cavernous sinus thrombosis, a blood clot develops in the sinus cavernous structure to prevent the infection from spreading to brain, but it often blocks the blood flow out of the brain. Septic cases of cavernous sinus thrombosis are usually caused by central facial infections, especially within the danger triangle of the face (from the corners of the mouth to the bridge of the nose). The main sources of infection include: Mastoiditis, otitis media, abscess, cellulitis,sinusitis and dental infections or procedures. The other rare causes of cavernous sinus thrombosis include: fungal infections, severe head injuries, autoimmune conditions such as lupus and pregnancy.


Causes

It is understood that the main cause of cavernous sinus thrombosis is bacterial infections. Septic cases of cavernous sinus thrombosis are usually caused by central facial infections, especially within the danger triangle of the face (from the corners of the mouth to the bridge of the nose). Common causes of cavernous sinus thrombosis may include: Staphylococcus aureus (two-thirds of cases) and Streptococcus species (approximately 20% of cases). Less common causes of cavernous sinus thrombosis include: Pneumococcus, Staphylococcus lugdunensis endocarditis, gram-negative species such as Proteus, hemophilus, Pseudomonas, Fusobacterium, Bacteroides, gram-positive species, Fungal infections, severe head injuries, autoimmune conditions such as lupus and Pregnancy. The main sources of infection in cavernous sinus thrombosis include: Mastoiditis, Otitis media, Abscess, cellulitis, Sinusitis, dental infections or procedures and endocarditis.

Differentiating cavernous sinus thrombosis from Other Diseases

Cavernous sinus thrombosis must be differentiated from other diseases that cause severe headache, pain with eye movements, high fever, proptosis, periorbital swelling, and ophthalmoplegia, such as orbital cellulitis, acute Angle-Closure Glaucoma, intracranial tumors and, carotid cavernous fistula and tolosa-Hunt syndrome.

Epidemiology and Demographics

The prevalence of cavernous sinus thrombosis is approximately 1.32–1.57 per 100,000 individuals worldwide. The mortality rate of cavernous sinus thrombosis is approximately 20%. The combination of anticoagulants with antibiotics in treatment of cavernous sinus thrombosis has significantly decreased the mortality rate of it. Patients of all age groups may develop cavernous sinus thrombosis. The incidence of cavernous sinus thrombosis significantly increases with age. women are more commonly affected by cavernous sinus thrombosis than men. The women to men ratio is approximately 3.7–5.3 to 1.

Risk Factors

Common risk factors in the development of cavernous sinus thrombosis include: Neoplasms, facial infections, sinusitis, otitis media, dental infections, sepsis, factor V Leiden mutation, Prothrombin G20210A mutation, antithrombin III deficiency, protein C or S deficiency, increased factor VIII, antiphospholipid antibody syndrome, hyperhomocysteinemia, heparin-induced thrombocytopenia, pregnancy, obesity, dehydration, autoimmune disease, uncontrolled diabetes, steroid use, chemotherapy, oral contraceptives or hormone replacement therapy and inflammatory bowel diseases. Less common risk factors in the development of cavernous sinus thrombosis include: Puerperium, fibrous thyroiditis, arterio-venous malformations and immunosuppression.

Screening

Common risk factors in the development of cavernous sinus thrombosis include: Neoplasms, facial infections, sinusitis, otitis media, dental infections, sepsis, factor V Leiden mutation, Prothrombin G20210A mutation, antithrombin III deficiency, protein C or S deficiency, increased factor VIII, antiphospholipid antibody syndrome, hyperhomocysteinemia, heparin-induced thrombocytopenia, pregnancy, obesity, dehydration, autoimmune disease, uncontrolled diabetes, steroid use, chemotherapy, oral contraceptives or hormone replacement therapy and inflammatory bowel diseases. Less common risk factors in the development of cavernous sinus thrombosis include: Puerperium, fibrous thyroiditis, arterio-venous malformations andimmunosuppression.

Natural History, Complications, and Prognosis

The symptoms of cavernous sinus thrombosis may vary depending upon the anatomical structures involved. The most common symptoms of cavernous sinus thrombosis include: Severe holocranial and bifrontal headache whit increasing severity, fever, Proptosis, Chemosis, external ophthalmoplegia, periorbital swelling and redness in one or both eyes. Other symptoms of cavernous sinus thrombosis include: Drooping eyelids, Decreased visual acuity, Vision loss or double vision, Inability to move the eye, periorbital sensory loss, pain or numbness around the face or eyes, fatigue, Seizures and Lethargy. Common complications of cavernous sinus thrombosis include: Death, bilateral blindness, Seizures, total ophthalmoplegia, Anisocoria, Meningitis, Intracerebral hemorrhage, Facial palsy, Hemiparesis, venous infarction, Ptosis and Hypopituitarism. Prognosis better as diagnosis is increasing made with imaging instead of autopsy, with mortality rates down from 100% to 6.5% in a recent review of 76 patients. Poor prognostic features include: Rapid progression, Coma, extremes of age, focal signs and symptoms, Hemorrhagic infarct and serious underlying cause.


Diagnosis

Diagnostic Study of Choice

Magnetic resonance imaging (MRI) with MR venography is the gold standard test for the diagnosis of cavernous sinus thrombosis. The following findings on performing MRI are confirmatory for cavernous sinus thrombosis: Absent flow void in T1 and T2 and signal characteristics vary depending on the age of the thrombus but will be abnormal. Contrast-enhancement or lack of is not a reliable indicator as organising thrombus can enhance. Diagnosis can generally be made on venography.

History and Symptoms

Patients with cavernous sinus thrombosis may have a positive history of: Neoplasms, facial infections, sinusitis, otitis media, dental infections, sepsis, factor V Leiden mutation, Prothrombin G20210A mutation, antithrombin III deficiency, protein C or S deficiency, increased factor VIII, antiphospholipid antibody syndrome, hyperhomocysteinemia, heparin-induced thrombocytopenia, pregnancy, obesity, dehydration, autoimmune disease, uncontrolled diabetes, steroid use, chemotherapy, oral contraceptives or hormone replacement therapy and inflammatory bowel diseases. The symptoms of cavernous sinus thrombosis may vary depend on the anatomical structures involved. The most common symptoms of cavernous sinus thrombosis include: Severe holocranial and bifrontal headache whit increasing severity, fever, Proptosis, Chemosis, external ophthalmoplegia, periorbital swelling and redness in one or both eyes. Other symptoms of cavernous sinus thrombosis include: Drooping eyelids, Decreased visual acuity, Vision loss or double vision, Inability to move the eye, periorbital sensory loss, pain or numbness around the face or eyes, fatigue, Seizures and Lethargy.

Physical Examination

Physical examination of patients with cavernous sinus thrombosis is usually remarkable for high grade fever, Tachycardia with regular pulse, Tachypnea, low blood pressure with normal pulse pressure, Pallor of skin, Altered mental status, Periorbital edema (initially unilateral but typically bilateral), unilateral or bilateral exophthalmos, abnormal extra-ocular movements from third, fourth and sixth cranial neuropathy, non-reactive pupils to neither light nor accommodation (from paralysis of the iris and ciliary body), lid erythema, horner syndrome (ptosis, miosis, and anhidrosis), Chemosis, Ptosis, Proptosis (due to impaired venous drainage of orbit, painful eye movement, Papilledema, retinal hemorrhages, decreased visual acuity, Photophobia, pulsating conjunctiva, facial tenderness, impaired corneal reflex, blindness, stiff neck, Photophobia, Hyperreflexia, generalised weakness, downgoing plantar reflex, Ptosis and Hemiparesis.

Laboratory Findings

Laboratory findings consistent with the diagnosis of cavernous sinus thrombosis include: Neutrophilic-predominant leukocytosis, lumbar puncture may be used to detect possible meningitis, positive blood culture, metabolic acidosis, hypernatremia and elevated ESR and CRP.

Electrocardiogram

There are no ECG findings associated with cavernous sinus thrombosis.

X-ray

The x-ray usually is not used in diagnosis of cavernous sinus thrombosis as the MRI and CT scan have a very better diagnostic value.

Echocardiography and Ultrasound

The echocardiography and ultrasound usually are not used in diagnosis of cavernous sinus thrombosis as the MRI and CT scan have a very better diagnostic value.

CT scan

High-resolution contrast-enhanced CT scan is useful in the assessment of cases with clinical features of cavernous sinus thrombosis. In early stages of the disease the CT and MRI findings may be normal. Findings on CT scan suggestive of cavernous sinus thrombosis include: Irregular filling defects within the cavernous sinus, thickening of the superior ophthalmic vein, poor enhancement of the cavernous sinus, hypodensity in the region of the cavernous sinus, thickening and dilation of the superior ophthalmic vein and opacification of the paranasal sinuses and ethmoidal air cells.

MRI

Magnetic resonance imaging (MRI) with MR venography is the gold standard test for the diagnosis of cavernous sinus thrombosis. The following findings on performing MRI are confirmatory for cavernous sinus thrombosis: Absent flow void in T1 and T2 and signal characteristics vary depending on the age of the thrombus but will be abnormal. Contrast-enhancement or lack of is not a reliable indicator as organising thrombus can enhance. Diagnosis can generally be made on venography.

Other Imaging Findings

There are no other imaging findings associated with cavernous sinus thrombosis.

Other Diagnostic Studies

There are no other diagnostic studies associated with cavernous sinus thrombosis.

Treatment

Medical Therapy

Cavernous sinus thrombosis is a medical emergency. Pharmacologic medical therapies for cavernous sinus thrombosis include antithombotic agents, antibiotics, and drugs such as mannitol, steroids and acetazolamide to decrease the intracranial pressure. Empiric antimicrobial therapy for septic thrombosis of cavernous or dural venous sinus includes metronidazole plus either nafcillin or oxacillin with either ceftriaxone or cefotaxime. Generally, the preferred empiric regimen for the treatment of cavernous sinus thrombosis is (Vancomycin 30–45 mg/kg IV q8–12h for 3-4 weeks OR Nafcillin 2 g IV q4h for 3-4 weeks OR Oxacillin 2 g IV q4h for 3-4 weeks) AND (Ceftriaxone 2 g IV q12h for 3-4 weeks OR Cefotaxime 8–12 g/day IV q4–6h for 3-4 weeks) AND Metronidazole 7.5 mg/kg IV q6h for 3-4 weeks. If the risk of MRSA is high, vancomycin should be used instead of either nafcillin or oxacillin. Other pharmacologic therapies include antithrombotic agents (usually LMWH) to prevent clot formation, steroid therapy (e.g. Dexamethasone 10 mg q6h) for symptomatic relief, and mannitol and acetazolamide to reduce the elevated intracranial pressure. Antiepileptic therapy should be administered only if patients develop seizures.

Interventions

Early endovascular therapy may help preserve vision in patients in patients with acute cavernous sinus thrombosis. Combination of medical and surgical interventions may be in management of cavernous sinus thrombosis. Endovascular therapy of cerebral venous thrombosis using approaches to intracranial recanalization include: Thrombolysis and thrombectomy. This interventions are not well described and there are few studies about this interventions. Successful recanalization of the bilateral cavernous sinuses and superior ophthalmic veins was achieved in some studies without complication.

Surgery

Surgical intervention is not recommended for the management of cavernous sinus thrombosis.

Primary Prevention

There are no established measures for the primary prevention of cavernous sinus thrombosis.

Secondary Prevention

There are no established measures for the primary prevention of cavernous sinus thrombosis.

References


Template:WikiDoc Sources

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

Cerebral sinus thrombosis was first discovered by Ribes a french physician, in 1825. Rabies discovers the cavernous sinus thrombosis from the autopsy of a 45-year-old patient with headaches, epileptic seizures and delirium. The first postpartum cerebral sinus thrombosis first discovered by John Abercrombie, a Scottish physician, in a 24-year-old woman who developed headache and seizures 2 weeks after an unremarkable delivery In 1828. A subsequent autopsy revealed thrombosis of the superior sagittal sinus and cortical veins.

Historical Perspective

Discovery

  • Cerebral sinus thrombosis was first discovered by Ribes a french physician, in 1825.[1]
  • Rabies discovers the cavernous sinus thrombosis from the autopsy of a 45-year-old patient with headaches, epileptic seizures and delirium.[1]
  • The first postpartum cerebral sinus thrombosis first discovered by John Abercrombie, a Scottish physician, in a 24-year-old woman who developed headache and seizures 2 weeks after an unremarkable delivery In 1828.[2]

References

  1. 1.0 1.1 Özgönül C, Ceylan OM, Mutlu FM, Altınsoy Hİ, Aparcı M (2015). “Abducens Palsy Due to Cerebral Venous Sinus Thrombosis in a Patient with Heart Failure”. Turk J Ophthalmol. 45 (4): 179–181. doi:10.4274/tjo.94468. PMC 5082278. PMID 27800228.
  2. Luo Y, Tian X, Wang X (2018). “Diagnosis and Treatment of Cerebral Venous Thrombosis: A Review”. Front Aging Neurosci. 10: 2. doi:10.3389/fnagi.2018.00002. PMC 5797620. PMID 29441008.

Template:WH Template:WS

Pathophysiology


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

The cavernous sinus which is a true dural venous sinus, is irregularly shaped, trabeculated cavities in the base of the skull. The cavernous sinus receives blood via the superior and inferior ophthalmic veins through the: Superior orbital fissure and superficial cortical veins. Cavernous sinus is connected to the basilar plexus of veins posteriorly. There are some important nerves and arteries pass through the cavernous sinus, include: The internal carotid artery (carotid siphon), cranial nerve III, cranial nerve IV, cranial nerve V branches and Cranial nerve VII. Infection from the face may reach the cavernous sinus through its many anastomotic connections, with severe consequences. The cavernous sinus drains by two larger channels, the superior and inferior petrosal sinuses, ultimately into the internal jugular vein via the sigmoid sinus, also draining with emissary vein to pterygoid plexus. These sinuses are just lateral and superior to the sphenoid sinus and are immediately posterior to the optic chiasm. Each cavernous sinus is formed between layers of the dura mater, and multiple connections exist between the 2 sinuses. It is understood that the main cause of cavernous sinus thrombosis is bacterial infections. Staphylococcus aureus may account for two-thirds of cases of cavernous sinus thrombosis. Other typical organisms include: streptococcus species (approximately 20% of cases), Pneumococcus (5%),gram-negative species such as Proteus, hemophilus, Pseudomonas, Fusobacterium, Bacteroides and gram-positive species such as Corynebacterium and Actinomyces. In cavernous sinus thrombosis, a blood clot develops in the sinus cavernous structure to prevent the infection from spreading to brain, but it often blocks the blood flow out of the brain. Septic cases of cavernous sinus thrombosis are usually caused by central facial infections, especially within the danger triangle of the face (from the corners of the mouth to the bridge of the nose). The main sources of infection include: Mastoiditis, Otitis media, Abscess, Cellulitis,Sinusitis and dental infections or procedures. The other rare causes of cavernous sinus thrombosis include: Fungal infections, severe head injuries, autoimmune conditions such as lupus and Pregnancy.

Pathophysiology

The cavernous sinus which is a true dural venous sinus, is irregularly shaped, trabeculated cavities in the base of the skull.[1][2][3]

The cavernous sinus receives blood via the superior and inferior ophthalmic veins through the:[1][4][2][3]

Cavernous sinus is connected to the basilar plexus of veins posteriorly.

There are some important nerves and arteries pass through the cavernous sinus, include:[4][2][3]

Infection from the face may reach the cavernous sinus through its many anastomotic connections, with severe consequences. The cavernous sinus drains by two larger channels, the superior and inferior petrosal sinuses, ultimately into the internal jugular vein via the sigmoid sinus, also draining with emissary vein to pterygoid plexus. These sinuses are just lateral and superior to the sphenoid sinus and are immediately posterior to the optic chiasm. Each cavernous sinus is formed between layers of the dura mater, and multiple connections exist between the 2 sinuses.[3][5]

Pathogenesis

  • In cavernous sinus thrombosis, a blood clot develops in the sinus cavernous structure to prevent the infection from spreading to brain, but it often blocks the blood flow out of the brain.[6][5]

Associated Conditions

References

  1. 1.0 1.1 Chaloupka JC, Goller D, Goldberg RA, Duckwiler GR, Martin NA, Viñuela F (1993). “True anatomical compartmentalization of the cavernous sinus in a patient with bilateral cavernous dural arteriovenous fistulae. Case report”. J Neurosurg. 79 (4): 592–5. doi:10.3171/jns.1993.79.4.0592. PMID 8410230.
  2. 2.0 2.1 2.2 Bakan AA, Alkan A, Kurtcan S, Aralaşmak A, Tokdemir S, Mehdi E; et al. (2015). “Cavernous Sinus: A Comprehensive Review of its Anatomy, Pathologic Conditions, and Imaging Features”. Clin Neuroradiol. 25 (2): 109–25. doi:10.1007/s00062-014-0360-0. PMID 25410584.
  3. 3.0 3.1 3.2 3.3 Marinkovic S, Gibo H, Vucevic R, Petrovic P (2001). “Anatomy of the cavernous sinus region”. J Clin Neurosci. 8 Suppl 1: 78–81. doi:10.1054/jocn.2001.0883. PMID 11386832.
  4. 4.0 4.1 Kehrli P, Maillot C, Wolff MJ (1996). “The venous system of the lateral sellar compartment (cavernous sinus): an histological and embryological study”. Neurol Res. 18 (5): 387–93. PMID 8916052.
  5. 5.0 5.1 5.2 5.3 5.4 5.5 Varshney S, Malhotra M, Gupta P, Gairola P, Kaur N (2015). “Cavernous sinus thrombosis of nasal origin in children”. Indian J Otolaryngol Head Neck Surg. 67 (1): 100–5. doi:10.1007/s12070-014-0805-4. PMC 4298578. PMID 25621244.
  6. 6.0 6.1 6.2 6.3 Clifford-Jones RE, Ellis CJ, Stevens JM, Turner A (1982). “Cavernous sinus thrombosis”. J Neurol Neurosurg Psychiatry. 45 (12): 1092–7. PMC 491689. PMID 7161604.
  7. Venezio FR, Naidich TP, Shulman ST (1982). “Complications of mastoiditis with special emphasis on venous sinus thrombosis”. J Pediatr. 101 (4): 509–13. PMID 7119951.
  8. Kuczkowski J (2007). “[Thrombophlebitis of venous sinuses in otitis media]”. Otolaryngol Pol. 61 (5): 769–73. doi:10.1016/S0030-6657(07)70523-1. PMID 18552016.
  9. Verma R, Junewar V, Singh RK, Ram H, Pal US (2013). “Bilateral cavernous sinus thrombosis and facial palsy as complications of dental abscess”. Natl J Maxillofac Surg. 4 (2): 252–5. doi:10.4103/0975-5950.127664. PMC 3961908. PMID 24665189.
  10. Allegrini D, Reposi S, Nocerino E, Pece A (2017). “Odontogenic orbital cellulitis associated with cavernous sinus thrombosis and pulmonary embolism: a case report”. J Med Case Rep. 11 (1): 164. doi:10.1186/s13256-017-1309-0. PMC 5477346. PMID 28629401.
  11. Komatsu H, Matsumoto F, Kasai M, Kurano K, Sasaki D, Ikeda K (2013). “Cavernous sinus thrombosis caused by contralateral sphenoid sinusitis: a case report”. Head Face Med. 9: 9. doi:10.1186/1746-160X-9-9. PMC 3605125. PMID 23497466.
  12. Yeo GS, Kim HY, Kim H, Kwak EJ, Jung YS, Park HS; et al. (2014). “Cavernous sinus thrombosis caused by a dental infection: a case report”. J Korean Assoc Oral Maxillofac Surg. 40 (4): 195–8. doi:10.5125/jkaoms.2014.40.4.195. PMC 4170663. PMID 25247150.
  13. Munjal M, Khurana AS (2004). “Fungal infections and cavernous sinus thrombosis”. Indian J Otolaryngol Head Neck Surg. 56 (3): 235–7. doi:10.1007/BF02974362. PMC 3451890. PMID 23120086.
  14. Ghuman MS, Salunke P, Sahoo SK, Kaur S (2016). “Cerebral venous sinus thrombosis in closed head trauma: A call to look beyond fractures and hematomas!”. J Emerg Trauma Shock. 9 (1): 37–8. doi:10.4103/0974-2700.173865. PMC 4766763. PMID 26957825.
  15. Singh RK, Bhoi SK, Kalita J, Misra UK (2017). “Cerebral Venous Sinus Thrombosis Presenting Feature of Systemic Lupus Erythematosus”. J Stroke Cerebrovasc Dis. 26 (3): 518–522. doi:10.1016/j.jstrokecerebrovasdis.2016.12.001. PMID 28065614.
  16. López F, Santamarta E, Martínez P, Sáiz-Ayala A, Llorente JL (2017). “Cavernous sinus thrombosis during pregnancy”. Auris Nasus Larynx. 44 (2): 232–236. doi:10.1016/j.anl.2016.04.006. PMID 27146007.

Template:WH Template:WS

Causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

It is understood that the main cause of cavernous sinus thrombosis is bacterial infections. Septic cases of cavernous sinus thrombosis are usually caused by central facial infections, especially within the danger triangle of the face (from the corners of the mouth to the bridge of the nose). Common causes of cavernous sinus thrombosis may include: Staphylococcus aureus (two-thirds of cases) and Streptococcus species (approximately 20% of cases). Less common causes of cavernous sinus thrombosis include: Pneumococcus, Staphylococcus lugdunensis endocarditis, gram-negative species such as Proteus, hemophilus, Pseudomonas, Fusobacterium, Bacteroides, gram-positive species, Fungal infections, severe head injuries, autoimmune conditions such as lupus and Pregnancy. The main sources of infection in cavernous sinus thrombosis include: Mastoiditis, Otitis media, Abscess, cellulitis, Sinusitis, dental infections or procedures and endocarditis.

Causes

It is understood that the main cause of cavernous sinus thrombosis is bacterial infections.[1][2]

Common Causes

Septic cases of cavernous sinus thrombosis are usually caused by central facial infections, especially within the danger triangle of the face (from the corners of the mouth to the bridge of the nose).[1][2]

Common causes of cavernous sinus thrombosis may include:[1][2]

Less Common Causes

Less common causes of cavernous sinus thrombosis include:[1][2][3][4][5][6][7]

Sources of infection

The main sources of infection in cavernous sinus thrombosis include:

Causes by Organ System

Cardiovascular Staphylococcus lugdunensis endocarditis[7]
Chemical/Poisoning No underlying causes
Dental
Dermatologic No underlying causes
Drug Side Effect No underlying causes
Ear Nose Throat
Endocrine No underlying causes
Environmental No underlying causes
Gastroenterologic No underlying causes
Genetic No underlying causes
Hematologic No underlying causes
Iatrogenic No underlying causes
Infectious Disease
Musculoskeletal/Orthopedic No underlying causes
Neurologic No underlying causes
Nutritional/Metabolic No underlying causes
Obstetric/Gynecologic Pregnancy[14]
Oncologic No underlying causes
Ophthalmologic No underlying causes
Overdose/Toxicity No underlying causes
Psychiatric No underlying causes
Pulmonary No underlying causes
Renal/Electrolyte No underlying causes
Rheumatology/Immunology/Allergy Autoimmune conditions such as lupus[15]
Sexual No underlying causes
Trauma Severe head injuries[16]
Urologic No underlying causes
Miscellaneous No underlying causes

References

  1. 1.0 1.1 1.2 1.3 Varshney S, Malhotra M, Gupta P, Gairola P, Kaur N (2015). “Cavernous sinus thrombosis of nasal origin in children”. Indian J Otolaryngol Head Neck Surg. 67 (1): 100–5. doi:10.1007/s12070-014-0805-4. PMC 4298578. PMID 25621244.
  2. 2.0 2.1 2.2 2.3 Clifford-Jones RE, Ellis CJ, Stevens JM, Turner A (1982). “Cavernous sinus thrombosis”. J Neurol Neurosurg Psychiatry. 45 (12): 1092–7. PMC 491689. PMID 7161604.
  3. Munjal M, Khurana AS (2004). “Fungal infections and cavernous sinus thrombosis”. Indian J Otolaryngol Head Neck Surg. 56 (3): 235–7. doi:10.1007/BF02974362. PMC 3451890. PMID 23120086.
  4. Ghuman MS, Salunke P, Sahoo SK, Kaur S (2016). “Cerebral venous sinus thrombosis in closed head trauma: A call to look beyond fractures and hematomas!”. J Emerg Trauma Shock. 9 (1): 37–8. doi:10.4103/0974-2700.173865. PMC 4766763. PMID 26957825.
  5. Singh RK, Bhoi SK, Kalita J, Misra UK (2017). “Cerebral Venous Sinus Thrombosis Presenting Feature of Systemic Lupus Erythematosus”. J Stroke Cerebrovasc Dis. 26 (3): 518–522. doi:10.1016/j.jstrokecerebrovasdis.2016.12.001. PMID 28065614.
  6. López F, Santamarta E, Martínez P, Sáiz-Ayala A, Llorente JL (2017). “Cavernous sinus thrombosis during pregnancy”. Auris Nasus Larynx. 44 (2): 232–236. doi:10.1016/j.anl.2016.04.006. PMID 27146007.
  7. 7.0 7.1 7.2 Nagarakanti S, Bishburg E, Brown M (2016). “Cavernous Sinus Thrombosis due to Streptococcus mitis and Staphylococcus lugdunensis”. J Clin Diagn Res. 10 (9): OD13–OD14. doi:10.7860/JCDR/2016/21521.8545. PMC 5072000. PMID 27790500.
  8. 8.0 8.1 Venezio FR, Naidich TP, Shulman ST (1982). “Complications of mastoiditis with special emphasis on venous sinus thrombosis”. J Pediatr. 101 (4): 509–13. PMID 7119951.
  9. 9.0 9.1 Kuczkowski J (2007). “[Thrombophlebitis of venous sinuses in otitis media]”. Otolaryngol Pol. 61 (5): 769–73. doi:10.1016/S0030-6657(07)70523-1. PMID 18552016.
  10. 10.0 10.1 10.2 Verma R, Junewar V, Singh RK, Ram H, Pal US (2013). “Bilateral cavernous sinus thrombosis and facial palsy as complications of dental abscess”. Natl J Maxillofac Surg. 4 (2): 252–5. doi:10.4103/0975-5950.127664. PMC 3961908. PMID 24665189.
  11. 11.0 11.1 Allegrini D, Reposi S, Nocerino E, Pece A (2017). “Odontogenic orbital cellulitis associated with cavernous sinus thrombosis and pulmonary embolism: a case report”. J Med Case Rep. 11 (1): 164. doi:10.1186/s13256-017-1309-0. PMC 5477346. PMID 28629401.
  12. 12.0 12.1 Komatsu H, Matsumoto F, Kasai M, Kurano K, Sasaki D, Ikeda K (2013). “Cavernous sinus thrombosis caused by contralateral sphenoid sinusitis: a case report”. Head Face Med. 9: 9. doi:10.1186/1746-160X-9-9. PMC 3605125. PMID 23497466.
  13. 13.0 13.1 Yeo GS, Kim HY, Kim H, Kwak EJ, Jung YS, Park HS; et al. (2014). “Cavernous sinus thrombosis caused by a dental infection: a case report”. J Korean Assoc Oral Maxillofac Surg. 40 (4): 195–8. doi:10.5125/jkaoms.2014.40.4.195. PMC 4170663. PMID 25247150.
  14. López F, Santamarta E, Martínez P, Sáiz-Ayala A, Llorente JL (2017). “Cavernous sinus thrombosis during pregnancy”. Auris Nasus Larynx. 44 (2): 232–236. doi:10.1016/j.anl.2016.04.006. PMID 27146007.
  15. Singh RK, Bhoi SK, Kalita J, Misra UK (2017). “Cerebral Venous Sinus Thrombosis Presenting Feature of Systemic Lupus Erythematosus”. J Stroke Cerebrovasc Dis. 26 (3): 518–522. doi:10.1016/j.jstrokecerebrovasdis.2016.12.001. PMID 28065614.
  16. Ghuman MS, Salunke P, Sahoo SK, Kaur S (2016). “Cerebral venous sinus thrombosis in closed head trauma: A call to look beyond fractures and hematomas!”. J Emerg Trauma Shock. 9 (1): 37–8. doi:10.4103/0974-2700.173865. PMC 4766763. PMID 26957825.

Template:WH Template:WS

Differentiating Cavernous sinus thrombosis from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

Cavernous sinus thrombosis must be differentiated from other diseases that cause severe headache, pain with eye movements, high fever, proptosis, periorbital swelling, and ophthalmoplegia, such as orbital cellulitis, acute Angle-Closure Glaucoma, intracranial tumors and, carotid cavernous fistula and tolosa-Hunt syndrome.

Differentiating cavernous sinus thrombosis] from other Diseases

Cavernous sinus thrombosis must be differentiated from other diseases that cause severe headache, pain with eye movements, high fever, proptosis, periorbital swelling, and ophthalmoplegia, such as orbital cellulitis, acute Angle-Closure Glaucoma, intracranial tumors and, carotid cavernous fistula and tolosa-Hunt syndrome.[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]

Diseases Clinical manifestations Para-clinical findings Additional findings
Symptoms Physical examination
Lab Findings
Severe headache High fever Pain with eye movements Proptosis Periorbital swelling and redness in one or both eyes Ophthalmoplegia Elevated ESR and CRP Positive blood culture Neutrophilic-predominant leukocytosis
Cavernous sinus thrombosis ++ ++ ++ ++ ++ ++ ++ ++ ++
Orbital cellulitis + + +++ +++ +++ ++ ++ + +
  • It may be acute or chronic.
  • May lead to cavernous sinus thrombosis.
Acute Angle-Closure Glaucoma +++ _ ++ _/+ _ _ _ _ _
Tumors such as: + _ _/+ _/+ _ ++ _/+ _ _/+ In most cases of intracranial tumors the symptoms progression is not fast.
Lytic bone lesions near the sphenoid sinus or sella turcica + _ _ _ _ ++ _ _ _ Slow progression in most cases
Carotid cavernous fistula + _ + + _/+ _/+ _ _ _
  • Patients usually present with sudden or insidious onset of redness in one eye, associated with progressive proptosis or bulging
  • Bruit (a humming sound within the skull due to high blood flow through the arteriovenous fistula) may be heard
Cavernous hemangioma + _ + + _/+ _/+ _ _ _
  • Cavernous hemangioma is found in women more frequently than men, most commonly between the ages of 20-40
Tolosa-Hunt syndrome + _ + _/+ _ + _ _ _/+ Symptoms are usually limited to one side of the head, and in most cases the individual affected will experience intense, sharp pain and paralysis of muscles around the eye

References

  1. Clifford-Jones RE, Ellis CJ, Stevens JM, Turner A (1982). “Cavernous sinus thrombosis”. J Neurol Neurosurg Psychiatry. 45 (12): 1092–7. PMC 491689. PMID 7161604.
  2. Arian M, Kamali A, Tabatabaeichehr M, Arashnia P (2016). “Septic Cavernous Sinus Thrombosis: A Case Report”. Iran Red Crescent Med J. 18 (8): e34961. doi:10.5812/ircmj.34961. PMC 5068248. PMID 27781123.
  3. Zahller M, Spector RH, Skoglund RR, Digby D, Nyhan WL (1980). “Cavernous sinus thrombosis”. West J Med. 133 (1): 44–8. PMC 1272185. PMID 7222646.
  4. Chaudhry IA, Al-Rashed W, Arat YO (2012). “The hot orbit: orbital cellulitis”. Middle East Afr J Ophthalmol. 19 (1): 34–42. doi:10.4103/0974-9233.92114. PMC 3277022. PMID 22346113.
  5. Lowe RF (1962). “ACUTE ANGLE-CLOSURE GLAUCOMA: THE SECOND EYE: AN ANALYSIS OF 200 CASES”. Br J Ophthalmol. 46 (11): 641–50. PMC 510261. PMID 18170827.
  6. See JL, Aquino MC, Aduan J, Chew PT (2011). “Management of angle closure glaucoma”. Indian J Ophthalmol. 59 Suppl: S82–7. doi:10.4103/0301-4738.73690. PMC 3038501. PMID 21150039.
  7. Herholz K, Langen KJ, Schiepers C, Mountz JM (2012). “Brain tumors”. Semin Nucl Med. 42 (6): 356–70. doi:10.1053/j.semnuclmed.2012.06.001. PMC 3925448. PMID 23026359.
  8. Kheirollahi M, Dashti S, Khalaj Z, Nazemroaia F, Mahzouni P (2015). “Brain tumors: Special characters for research and banking”. Adv Biomed Res. 4: 4. doi:10.4103/2277-9175.148261. PMC 4300589. PMID 25625110.
  9. Maschio M (2012). “Brain tumor-related epilepsy”. Curr Neuropharmacol. 10 (2): 124–33. doi:10.2174/157015912800604470. PMC 3386502. PMID 23204982.
  10. Shownkeen H, Bova D, Origitano TC, Petruzzelli GJ, Leonetti JP (2001). “Carotid-cavernous fistulas: pathogenesis and routes of approach to endovascular treatment”. Skull Base. 11 (3): 207–18. PMC 1656855. PMID 17167622.
  11. Ellis JA, Goldstein H, Connolly ES, Meyers PM (2012). “Carotid-cavernous fistulas”. Neurosurg Focus. 32 (5): E9. doi:10.3171/2012.2.FOCUS1223. PMID 22537135.
  12. Chaudhry IA, Elkhamry SM, Al-Rashed W, Bosley TM (2009). “Carotid cavernous fistula: ophthalmological implications”. Middle East Afr J Ophthalmol. 16 (2): 57–63. doi:10.4103/0974-9233.53862. PMC 2813585. PMID 20142962.
  13. Kline LB, Hoyt WF (2001). “The Tolosa-Hunt syndrome”. J Neurol Neurosurg Psychiatry. 71 (5): 577–82. PMC 1737614. PMID 11606665.
  14. Paović J, Paović P, Bojković I, Nagulić M, Sredović V (2012). “Tolosa-Hunt syndrome–diagnostic problem of painful ophthalmoplegia”. Vojnosanit Pregl. 69 (7): 627–30. PMID 22838177.
  15. Halabi T, Sawaya R (2018). “Successful Treatment of Tolosa-Hunt Syndrome after a Single Infusion of Infliximab”. J Clin Neurol. 14 (1): 126–127. doi:10.3988/jcn.2018.14.1.126. PMC 5765250. PMID 29629550.

Template:WH Template:WS

Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

The prevalence of cavernous sinus thrombosis is approximately 1.32–1.57 per 100,000 individuals worldwide. The mortality rate of cavernous sinus thrombosis is approximately 20%. The combination of anticoagulants with antibiotics in treatment of cavernous sinus thrombosis has significantly decreased the mortality rate of it. Patients of all age groups may develop cavernous sinus thrombosis. The incidence of cavernous sinus thrombosis significantly increases with age. women are more commonly affected by cavernous sinus thrombosis than men. The women to men ratio is approximately 3.7–5.3 to 1.

Epidemiology and Demographics

Incidence

  • The prevalence of cavernous sinus thrombosis is approximately 1.32–1.57 per 100,000 individuals worldwide.[1][2]

Case-fatality rate/Mortality rate

  • The mortality rate of cavernous sinus thrombosis is approximately 20%.[3]

The combination of anticoagulants with antibiotics in treatment of cavernous sinus thrombosis has significantly decreased the mortality rate of it.[4]

Age

  • Patients of all age groups may develop cavernous sinus thrombosis.
  • The incidence of cavernous sinus thrombosis significantly increases with age.[4][5]

Gender

  • Women are more commonly affected by cavernous sinus thrombosis than men. The women to men ratio is approximately 3.7–5.3 to 1.[2][5]

References

  1. Devasagayam S, Wyatt B, Leyden J, Kleinig T (2016). “Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously Thought: A Retrospective Population-Based Study”. Stroke. 47 (9): 2180–2. doi:10.1161/STROKEAHA.116.013617. PMID 27435401.
  2. 2.0 2.1 Luo Y, Tian X, Wang X (2018). “Diagnosis and Treatment of Cerebral Venous Thrombosis: A Review”. Front Aging Neurosci. 10: 2. doi:10.3389/fnagi.2018.00002. PMC 5797620. PMID 29441008.
  3. Arian M, Kamali A, Tabatabaeichehr M, Arashnia P (2016). “Septic Cavernous Sinus Thrombosis: A Case Report”. Iran Red Crescent Med J. 18 (8): e34961. doi:10.5812/ircmj.34961. PMC 5068248. PMID 27781123.
  4. 4.0 4.1 Leo QJ, Bolger DT (2014). “Septic cavernous sinus thrombosis due to Campylobacter rectus infection”. BMJ Case Rep. 2014. doi:10.1136/bcr-2013-203351. PMC 4039913. PMID 24842357.
  5. 5.0 5.1 Karadas S, Milanlioglu A, Gönüllü H, Sayin R, Aydin MN (2014). “Cerebral venous sinus thrombosis presentation in emergency department in Van, Turkey”. J Pak Med Assoc. 64 (4): 370–4. PMID 24864625.

Template:WH Template:WS

Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

Common risk factors in the development of cavernous sinus thrombosis include: Neoplasms, facial infections, sinusitis, otitis media, dental infections, sepsis, factor V Leiden mutation, Prothrombin G20210A mutation, antithrombin III deficiency, protein C or S deficiency, increased factor VIII, antiphospholipid antibody syndrome, hyperhomocysteinemia, heparin-induced thrombocytopenia, pregnancy, obesity, dehydration, autoimmune disease, uncontrolled diabetes, steroid use, chemotherapy, oral contraceptives or hormone replacement therapy and inflammatory bowel diseases. Less common risk factors in the development of cavernous sinus thrombosis include: Puerperium, fibrous thyroiditis, arterio-venous malformations andimmunosuppression.

Risk Factors

Common risk factors in the development of cavernous sinus thrombosis include: Neoplasms, facial infections, sinusitis, otitis media, dental infections, sepsis, factor V Leiden mutation, Prothrombin G20210A mutation, antithrombin III deficiency, protein C or S deficiency, increased factor VIII, antiphospholipid antibody syndrome, hyperhomocysteinemia, heparin-induced thrombocytopenia, pregnancy, obesity, dehydration, autoimmune disease, uncontrolled diabetes, steroid use, chemotherapy, oral contraceptives or hormone replacement therapy and inflammatory bowel diseases.

Common Risk Factors

Less Common Risk Factors

References

  1. 1.0 1.1 Saadatnia M, Fatehi F, Basiri K, Mousavi SA, Mehr GK (2009). “Cerebral venous sinus thrombosis risk factors”. Int J Stroke. 4 (2): 111–23. doi:10.1111/j.1747-4949.2009.00260.x. PMID 19383052.
  2. Hickey WF, Garnick MB, Henderson IC, Dawson DM (1982). “Primary cerebral venous thrombosis in patients with cancer–a rarely diagnosed paraneoplastic syndrome. Report of three cases and review of the literature”. Am J Med. 73 (5): 740–50. PMID 6753578.
  3. Aggarwal K, Rastogi S, Joshi A, Kumar A, Chaurasia A, Prakash R (2017). “Cavernous sinus thrombosis following dental extraction: a rare case report and forgotten entity”. J Korean Assoc Oral Maxillofac Surg. 43 (5): 351–355. doi:10.5125/jkaoms.2017.43.5.351. PMC 5685866. PMID 29142871.
  4. Zuber M, Toulon P, Marnet L, Mas JL (1996). “Factor V Leiden mutation in cerebral venous thrombosis”. Stroke. 27 (10): 1721–3. PMID 8841317.
  5. Attia TH, Fawzi HA, Desouki IS (2015). “Cerebral venous sinus thrombosis in heterozygous prothrombin G20210A mutation in Egyptian child, with an excellent outcome”. Oxf Med Case Reports. 2015 (5): 284–7. doi:10.1093/omcr/omv035. PMC 4434574. PMID 26019885.
  6. Kumaravelu S, Gupta A, Singh KK (2008). “Cerebral Venous Thrombosis”. Med J Armed Forces India. 64 (4): 355–60. doi:10.1016/S0377-1237(08)80021-4. PMC 5035253. PMID 27688576.
  7. Ali N, Ayyub M, Khan SA (2014). “High prevalence of protein C, protein S, antithrombin deficiency, and Factor V Leiden mutation as a cause of hereditary thrombophilia in patients of venous thromboembolism and cerebrovascular accident”. Pak J Med Sci. 30 (6): 1323–6. doi:10.12669/pjms.306.5878. PMC 4320724. PMID 25674132.
  8. Bucurescu S (2014). “Recurrent cerebral venous sinus thrombosis in a patient with increased factor VIII activity, increased lipoprotein (a) level and leukocytosis: a case report”. J Vasc Interv Neurol. 7 (1): 8–10. PMC 4051910. PMID 24920982.
  9. Rudich DS, Yun SH, Liebling A, Silbert JE, Moeckel GW, Lesser RL (2015). “Antiphospholipid Antibody Syndrome: Raised Intracranial Pressure Without Cerebral Venous Sinus Thrombosis”. J Neuroophthalmol. 35 (4): 396–9. doi:10.1097/WNO.0000000000000277. PMID 26049680.
  10. Shen HC, Lo YK, Li JY, Lai PH (2007). “Familial hyperhomocysteinemia-related cerebral venous sinus thrombosis and pulmonary embolism: a case report”. Acta Neurol Taiwan. 16 (2): 98–101. PMID 17685134.
  11. Gleichgerrcht E, Lim MY, Turan TN (2017). “Cerebral Venous Sinus Thrombosis Due to Low-molecular-weight Heparin-induced Thrombocytopenia”. Neurologist. 22 (6): 241–244. doi:10.1097/NRL.0000000000000146. PMID 29095327.
  12. López F, Santamarta E, Martínez P, Sáiz-Ayala A, Llorente JL (2017). “Cavernous sinus thrombosis during pregnancy”. Auris Nasus Larynx. 44 (2): 232–236. doi:10.1016/j.anl.2016.04.006. PMID 27146007.
  13. Zuurbier SM, Arnold M, Middeldorp S, Broeg-Morvay A, Silvis SM, Heldner MR; et al. (2016). “Risk of Cerebral Venous Thrombosis in Obese Women”. JAMA Neurol. 73 (5): 579–84. doi:10.1001/jamaneurol.2016.0001. PMID 26974867.
  14. Kawahara I, Toyoda K, Hirose M, Kitagawa N (2018). “[Rapid Recanalization of Cerebral Venous Sinus Thrombosis Secondary to Severe Dehydration:A Case Report]”. No Shinkei Geka. 46 (1): 47–52. doi:10.11477/mf.1436203674. PMID 29362285.
  15. Ichord R (2017). “Cerebral Sinovenous Thrombosis”. Front Pediatr. 5: 163. doi:10.3389/fped.2017.00163. PMC 5529336. PMID 28798906.
  16. RUSSELL A, FEARING SJ (1955). “Cavernous sinus thrombosis in a diabetic; report of a case”. Oral Surg Oral Med Oral Pathol. 8 (4): 372–7. PMID 14370762.
  17. Weerasinghe D, Lueck CJ (2016). “Septic Cavernous Sinus Thrombosis: Case Report and Review of the Literature”. Neuroophthalmology. 40 (6): 263–276. doi:10.1080/01658107.2016.1230138. PMC 5120738. PMID 27928417.
  18. Sasidharan PK (2012). “Cerebral vein thrombosis misdiagnosed and mismanaged”. Thrombosis. 2012: 210676. doi:10.1155/2012/210676. PMC 3337512. PMID 22567255.
  19. Yadegari S, Ghorbani A, Miri SR, Abdollahi M, Rostami M (2016). “Clinical features, risk factors, and outcome of cerebral venous thrombosis in Tehran, Iran”. J Neurosci Rural Pract. 7 (4): 554–558. doi:10.4103/0976-3147.185512. PMC 5006468. PMID 27695236.
  20. Selvitop O, Poretti A, Huisman TA, Wagner MW (2015). “Cerebral sinovenous thrombosis in a child with Crohn’s disease, otitis media, and meningitis”. Neuroradiol J. 28 (3): 274–7. doi:10.1177/1971400915589688. PMC 4757291. PMID 26246095.
  21. Jungmann V, Werner R, Bergmann J, Daum J, Wöhrle JC, Dünnebacke J; et al. (2009). “[Postpartum cerebral venous sinus thrombosis after epidural anaesthesia]”. Anaesthesist. 58 (3): 268–72. doi:10.1007/s00101-008-1490-z. PMID 19107452.
  22. Vaidya B, Coulthard A, Goonetilleke A, Burn DJ, James RA, Kendall-Taylor P (1998). “Cerebral venous sinus thrombosis: a late sequel of invasive fibrous thyroiditis”. Thyroid. 8 (9): 787–90. doi:10.1089/thy.1998.8.787. PMID 9777750.
  23. Stiebel-Kalish H, Setton A, Nimii Y, Kalish Y, Hartman J, Huna Bar-On R; et al. (2002). “Cavernous sinus dural arteriovenous malformations: patterns of venous drainage are related to clinical signs and symptoms”. Ophthalmology. 109 (9): 1685–91. PMID 12208718.
  24. Bertz H, Laubenberger J, Steinfurth G, Finke J (1998). “Sinus venous thrombosis: an unusual cause for neurologic symptoms after bone marrow transplantation under immunosuppression”. Transplantation. 66 (2): 241–4. PMID 9701272.

Template:WH Template:WS

Natural History, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

The symptoms of cavernous sinus thrombosis may vary depend on the anatomical structures involved. The most common symptoms of cavernous sinus thrombosis include: Severe holocranial and bifrontal headache whit increasing severity, fever, Proptosis, Chemosis, external ophthalmoplegia, periorbital swelling and redness in one or both eyes. Other symptoms of cavernous sinus thrombosis include: Drooping eyelids, Decreased visual acuity, Vision loss or double vision, Inability to move the eye, periorbital sensory loss, pain or numbness around the face or eyes, fatigue, Seizures and Lethargy. Common complications of cavernous sinus thrombosis include: Death, bilateral blindness, Seizures, total ophthalmoplegia, Anisocoria, Meningitis, Intracerebral hemorrhage, Facial palsy, Hemiparesis, venous infarction, Ptosis and Hypopituitarism. Prognosis better as diagnosis is increasing made with imaging instead of autopsy, with mortality rates down from 100% to 6.5% in a recent review of 76 patients. Poor prognostic features include: Rapid progression, Coma, extremes of age, focal signs and symptoms, Hemorrhagic infarct and serious underlying cause.

Natural History, Complications, and Prognosis

Natural History

The symptoms of cavernous sinus thrombosis may vary depend on the anatomical structures involved.[1]

Complications

Prognosis

  • Prognosis better as diagnosis is increasing made with imaging instead of autopsy, with mortality rates down from 100% to 6.5% in a recent review of 76 patients.
  • Poor prognostic features:
  • Of note, if patient survives, outcome is better than for arterial infarct

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 Yeo GS, Kim HY, Kim H, Kwak EJ, Jung YS, Park HS; et al. (2014). “Cavernous sinus thrombosis caused by a dental infection: a case report”. J Korean Assoc Oral Maxillofac Surg. 40 (4): 195–8. doi:10.5125/jkaoms.2014.40.4.195. PMC 4170663. PMID 25247150.
  2. 2.0 2.1 Botta R, Donirpathi S, Yadav R, Kulkarni GB, Kumar MV, Nagaraja D (2017). “Headache Patterns in Cerebral Venous Sinus Thrombosis”. J Neurosci Rural Pract. 8 (Suppl 1): S72–S77. doi:10.4103/jnrp.jnrp_339_16. PMC 5602266. PMID 28936075.
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Mallick A, Pathak SD, Shankar S, Sati A (2015). “Early cavernous sinus thrombosis following unilateral pansinusitis in a child”. BMJ Case Rep. 2015. doi:10.1136/bcr-2014-208441. PMC 4422932. PMID 25917067.
  4. 4.0 4.1 Sha DJ, Qian J, Gu SS, Wang LN, Wang F, Xu Y (2018). “Cerebral venous sinus thrombosis complicated by seizures: a retrospective analysis of 69 cases”. J Thromb Thrombolysis. 45 (1): 186–191. doi:10.1007/s11239-017-1570-5. PMC 5756278. PMID 29039017.
  5. Clifford-Jones RE, Ellis CJ, Stevens JM, Turner A (1982). “Cavernous sinus thrombosis”. J Neurol Neurosurg Psychiatry. 45 (12): 1092–7. PMC 491689. PMID 7161604.
  6. Coutteel C, Leys A, Fossion E, Missotten L (1991). “Bilateral blindness in cavernous sinus thrombosis”. Int Ophthalmol. 15 (3): 163–71. PMID 2050471.
  7. 7.0 7.1 Bouraoui R, Bouladi M, Ben Romdhane B, Limaiem R, Mghaieth F, El Matri L (2016). “Ophthalmic artery occlusion with total ophtalmoplegia and anisocoria revealing cavernous sinus thrombosis”. Tunis Med. 94 (2): 145–7. PMID 27532532.
  8. Munckhof WJ, Krishnan A, Kruger P, Looke D (2008). “Cavernous sinus thrombosis and meningitis from community-acquired methicillin-resistant Staphylococcus aureus infection”. Intern Med J. 38 (4): 283–7. doi:10.1111/j.1445-5994.2008.01650.x. PMID 18380704.
  9. Pongmoragot J, Saposnik G (2012). “Intracerebral hemorrhage from cerebral venous thrombosis”. Curr Atheroscler Rep. 14 (4): 382–9. doi:10.1007/s11883-012-0260-1. PMID 22664979.
  10. Verma R, Junewar V, Singh RK, Ram H, Pal US (2013). “Bilateral cavernous sinus thrombosis and facial palsy as complications of dental abscess”. Natl J Maxillofac Surg. 4 (2): 252–5. doi:10.4103/0975-5950.127664. PMC 3961908. PMID 24665189.
  11. 11.0 11.1 Kamouchi M, Wakugawa Y, Okada Y, Kishikawa K, Matsuo R, Toyoda K; et al. (2006). “Venous infarction secondary to septic cavernous sinus thrombosis”. Intern Med. 45 (1): 25–7. PMID 16467601.
  12. Rodrigues R, Merchant R, Parekh S (1983). “Cavernous sinus thrombosis with retrobulbar mass and hemiplegia”. Indian J Pediatr. 50 (405): 457–9. PMID 6671735.
  13. Kraus CL, Culican SM (2012). “Challenging presentations of cavernous sinus thrombophlebitis”. J Ophthalmic Inflamm Infect. 2 (3): 133–6. doi:10.1007/s12348-011-0053-7. PMC 3438306. PMID 22139823.
  14. Silver HS, Morris LR (1983). “Hypopituitarism secondary to cavernous sinus thrombosis”. South Med J. 76 (5): 642–6. PMID 6302919.

Template:WH Template:WS

Diagnosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | CT | MRI | Other Imaging Findings | Other Diagnostic Studies

Treatment

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case Studies

Case #1

Acknowledgements

Acknowledgements

The content on this page was first contributed by: C. Michael Gibson M.S., M.D.


Template:WS

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH